

Сlinical registry of patients with recurrent pericarditis — RUDRA
https://doi.org/10.30629/0023-2149-2025-103-4-309-313
Abstract
Recurrent Pericarditis (RP) is a significant medical issue despite advancements in modern cardiology. The management of patients with this condition is associated with several challenges due to the variety of clinical manifestations, difficulties in differential diagnosis, lack of standardized treatment protocols, and a high likelihood of recurrences. Furthermore, there is insufficient data in the literature regarding the prevalence, structure, and characteristics of RP in the Russian population, which complicates the development of unified clinical protocols and recommendations. This article presents the rationale and description of the multicenter non-interventional registry of real clinical practice, RUDRA, whose primary objective is to study RP in the Russian population. The main focus is on analyzing the frequency, characteristics of the course, and outcomes of RP, including its idiopathic form. Patient data registration will be conducted in two parts—retrospective and prospective—allowing for a comprehensive analysis and the realization of all set objectives. The registry will investigate key aspects of etiology, diagnosis, treatment, and dynamic monitoring of patients with various forms of RP. The establishment and maintenance of the RUDRA registry may provide new and expanded opportunities for systematizing knowledge about RP, contributing to improved quality of medical care for patients suffering from this condition.
About the Authors
G. P. ArutyunovRussian Federation
Grigory P. Arutyunov — Doctor of Medical Sciences, Professor, President; Corresponding Member of the Russian Academy of Sciences, Head of the Department of Propaedeutics of Internal Diseases of the Faculty of Pediatrics; Honored Doctor of the Russian Federation
Moscow
T. I. Batluk
Russian Federation
Tatyana I. Batluk — Candidate of Medical Sciences, Leading Medical Adviser
Moscow
R. A. Bashkinov
Russian Federation
Roman A. Bashkinov — Assistant Professor of the Department of Therapy, Rheumatology, Examination of Temporary Disability and Quality of Medical Care with a course in Hematology and Transfusiology named after E.E. Eichwald; Leading medical Adviser
Saint Petersburg
Moscow
Е. Тарловская
Russian Federation
Ekaterina I. Tarlovskaya — Doctor of Medical Sciences, Professor, Vice-President; Head of the Department of Therapy and Cardiology
Moscow
Nizhny Novgorod
A. Yu. Vaskin
Russian Federation
Alexander Yu. Vaskin — Project Manager
Moscow
References
1. Ma Y., Wang Z., Mazurov V.I., Trofi mov E.A., Bashkinov R.A. Cardio-rheumatology: present and future. Part I. HERALD of North-Western State Medical University named after I.I. Mechnikov. 2024;16(3):5–18. (In Russian)]. DOI: 10.17816/mechnikov634480
2. Alfaddagh A., Martin S.S., Leucker T.M., Michos E.D., Blaha M.J., Lowenstein C.J., Jones S.R., Toth P.P. Infl ammation and cardiovascular disease: From mechanisms to therapeutics. Am. J. Prev. Cardiol. 2020;4:100130. DOI: 10.1016/j.ajpc.2020.100130
3. Arutyunov G.P., Paleev F.N., Tarlovskaya E.I., Moiseeva O.M., Arutyunov A.G., Koziolova N.A. et al. Pericarditis. Clinical Guidelines 2022. Russian Journal of Cardiology. 2023;28(3):5398 (In Russian)]. DOI:10.15829/1560-4071-2023-5398
4. Adler Y., Charron P., Imazio M., Badano L., Barón-Esquivias G., Bogaert J. et al.; ESC Scientifi c Document Group. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC)Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart. J. 2015;36(42):2921–2964. DOI: 10.1093/eurheartj/ehv318
5. Imazio M., Brucato A., Cemin R., Ferrua S., Maggiolini S., Beqaraj F. et al.; ICAP Investigators. A randomized trial of colchicine for acute pericarditis. N. Engl. J. Med. 2013;369(16):1522–8. DOI: 10.1056/NEJMoa1208536
6. Imazio M., Belli R., Brucato A., Cemin R., Ferrua S., Beqaraj F. et al. Effi cacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial. Lancet. 2014;383:2232–2237. DOI: 10.1016/S0140-6736(13)62709-9
7. Mauro A.G., Bonaventura A., Vecchié A., Mezzaroma E., Carbone S., Narayan P. et al. The Role of NLRP3 infl ammasome in pericarditis: potential for therapeutic approaches. JACC Basic Transl. Sci. 2021;6(2):137–150. DOI: 10.1016/j.jacbts.2020.11.016
8. Abbate A., Toldo S., Marchetti C., Kron J., Van Tassell B.W., Dinarello C.A. Interleukin-1 and the Infl ammasome as Therapeutic Targets in Cardiovascular Disease. Circ. Res. 2020;126(9):1260-1280. DOI: 10.1161/CIRCRESAHA.120.315937
9. Мячикова В.Ю., Маслянский А.Л., Моисеева О.М. Идиопатический рецидивирующий перикардит — новое орфанное аутовоспалительное заболевание? Ретроспективный анализ случаев идиопатического рецидивирующего перикардита и план рандомизированного, плацебо-контролируемого исследования для оценки терапевтической эффективности и безопасности блокатора ИЛ-1 (RPH-104). Кардиология. 2021;61(1):72–77 DOI: 10.18087/cardio.2021.1.n1475
10. Myachikova V.Yu, Maslyanskiy A.L., Moiseeva O.M. Idiopathic recurrent pericarditis — a new orphan autoinfl ammatory disease? A retrospective analysis of cases of idiopathic recurrent pericarditis and a design of а double-blind, randomized, placebo-controlled study to evaluate the effi cacy and safety of RPH-104 treatment in patients with idiopathic recurrent pericarditis. Kardiologiia. 2021;61(1):72-77. (In Russian). DOI: 10.18087/cardio.2021.1.n1475
11. Klein A., Cremer P., Kontzias A., Furqan M., Tubman R., Roy M. et al. US Database study of clinical burden and unmet need in recurrent pericarditis. J. Am. Heart Assoc. 2021;10(15):e018950. DOI: 10.1161/JAHA.120.018950
12. Imazio M., Bobbio M., Cecchi E., Demarie D., Pomari F., Moratti M. et al. Colchicine as fi rst-choice therapy for recurrent pericarditis: results of the CORE (COlchicine for REcurrent pericarditis) trial. Arch. Intern. Med. 2005;165(17):1987–91. DOI: 10.1001/archinte.165.17.1987
13. Imazio M., Brucato A., Cemin R., Ferrua S., Belli R., Maestroni S. et al.; CORP (COlchicine for Recurrent Pericarditis) Investigators. Colchicine for recurrent pericarditis (CORP): a randomized trial. Ann. Intern. Med. 2011;155(7):409–14. DOI: 10.7326/0003-4819-155-7-201110040-00359
14. Mazurov V.I., Trofi mov E.A., Samigullina R.R. Rheumatoid arthritis. In book. Clinical rheumatology. 3rd edition, revised and enlarged. A guide for doctors ed. V.I. Mazurov. M.E-noto. 2021:72–105. (In Russian)]. ISBN: 978-5-906023-26-1
15. Brucato A., Imazio M., Gattorno M., Lazaros G., Maestroni S., Carraro M. et al. Eff ect of anakinra on recurrent pericarditis among patients with colchicine resistance and corticosteroid dependence: The AIRTRIP randomized clinical trial. JAMA. 2016;316(18):1906-1912. DOI: 10.1001/jama.2016.15826
16. Klein A.L., Imazio M., Brucato A., Cremer P., LeWinter M., Abbate A. et al. RHAPSODY: Rationale for and design of a pivotal Phase 3 trial to assess effi cacy and safety of rilonacept, an interleukin-1α and interleukin-1β trap, in patients with recurrent pericarditis. Am. Heart J. 2020;228:81–90. DOI: 10.1016/j.ahj.2020.07.004
Review
For citations:
Arutyunov G.P., Batluk T.I., Bashkinov R.A., , Vaskin A.Yu. Сlinical registry of patients with recurrent pericarditis — RUDRA. Clinical Medicine (Russian Journal). 2025;103(4):309-313. (In Russ.) https://doi.org/10.30629/0023-2149-2025-103-4-309-313